Characteristics of pregnant women and ARTs for perinatal HIV prevention according to study.

<p>^a sdNVP either in the woman at onset of labor, in the infant or in both</p><p>^b only in women who did not receive LPV/r</p><p>Characteristics of pregnant women and ARTs for perinatal HIV prevention according to study.</p

The univariate and multivariable analyses of the HIV intra-partum transmission model using data from 3,707 HIV-1-infected mothers enrolled in the PHPT-1, PHPT-2, and PHPT-5 studies.

<p>^aRSE%, relative standard error (standard error of estimate / estimate*100)</p><p>^b Bayesian Information Criterion</p><p>^c Random effect of individuals: <i>η</i>~<i>N</i>(0,0.73²)</p><p>The univariate and multivariable analyses of the HIV intra-partum transmission model using data from 3,707 HIV-1-infected mothers enrolled in the PHPT-1, PHPT-2, and PHPT-5 studies.</p

Population parameter estimates of HIV time-course model for 3,759 HIV-1-infected mothers enrolled in the PHPT-1, PHPT-2, and PHPT-5 studies.

<p>^a SE, standard error of estimate</p><p>^b RSE%, relative standard error (standard error of estimate / estimate*100)</p><p>^c<i>σ</i>_<i>VL</i>, residual (square roots of variances)</p><p>Population parameter estimates of HIV time-course model for 3,759 HIV-1-infected mothers enrolled in the PHPT-1, PHPT-2, and PHPT-5 studies.</p

The univariate and multivariable analyses of the HIV <i>in-utero</i> model using data from 3,707 HIV-1-infected mothers enrolled in the PHPT-1, PHPT-2, and PHPT-5 studies.

<p>^a RSE%, relative standard error (standard error of estimate / estimate*100)</p><p>^b Bayesian Information Criterion</p><p>^c Random effect of individuals: <i>η</i>~<i>N</i>(0,0.527²)</p><p>The univariate and multivariable analyses of the HIV <i>in-utero</i> model using data from 3,707 HIV-1-infected mothers enrolled in the PHPT-1, PHPT-2, and PHPT-5 studies.</p

Transmission probabilities according to zidovudine duration, viral load at baseline/delivery, and nevirapine intake.

<p>A. Probability of <i>in-utero</i> HIV transmission as a function of zidovudine duration; B. Probability of <i>in-utero</i> HIV transmission as a function of viral load at baseline. The lines denote the median, 5^th and 95^thpercentiles of the model predictions. The open circles stand for the observed mean proportion of transmission, the solid vertical segments denote the corresponding 95% confidence intervals (numbers at top of each segment stand for the number of women in each time interval or VL interval). C. Probability of <i>intra-partum</i> HIV mother-to-child transmission as a function of viral load at delivery without single dose nevirapine; D. Probability of <i>intra-partum</i> HIV mother-to-child transmission as a function of viral load at delivery with single dose nevirapine.</p

Diagnostic plots for viral load time-course model.

<p>Top: 2a and 2b: Observed versus model predicted viral load values (expressed as log₁₀ copies) of the population and individual predictions respectively. Solid black circles, measure values; grey symbols, simulation of below the limit of quantification data. Line, identity line. Bottom: Visual predictive check plots. (2c) Women receiving only zidovudine (ZDV); (2d) women receiving zidovudine plus lopinavir/ritonavir (ZDV+LPV/r).The lines denote the median, 5^th and 95^th percentiles for the observed data. The grey areas stand for the 95% confidence intervals of the median, 5^th and 95^th model prediction percentiles.</p

Treatment changes and actions after viral rebound.

<p>Treatment changes and actions after viral rebound.</p

Confirmed HIV-1 RNA ≥ 50 copies/mL by 48, 96, 144 and 192 weeks.

<p>SCT = short cycle therapy, CT = continuous therapy.</p

Adverse events.

<p>Adverse events.</p

Virology, immunology and secondary endpoints over all follow-up.

<p>Virology, immunology and secondary endpoints over all follow-up.</p